Moffitt Cancer Center physician reviews how patients may reduce their risk for colon cancer
Healio.com – June 23
In this video, Mark S. Friedman, MD, of the Moffitt Cancer Center, discusses genetic and environmental risk factors that may increase the risk for developing colon cancer.
Ciena picked for Moffitt Cancer Center network
Telecompaper – June 22
Ciena announced that Moffitt Cancer Center, one of the largest cancer centers in the US based on patient volume, is deploying its own private enterprise network using packet optical technology from Ciena.
Tampa: Martinis for Moffitt 2016 – June 22
Martinis for Moffitt is our flagship event that supports Moffitt’s critical cancer research programs. It is one of the best fundraising events in the Tampa Bay Area, providing a unique blend of entertainment and networking, while raising money to fight a devastating disease.
Tumor cells have non-random, predictable characteristics, scientists say
UPI — June 21
Scientists at the Moffitt Cancer Center found in a study of breast cancer that cells closer to the center of a tumor are more attuned to using resources, while those at the outer edges specialize in cellular invasion that leads to tumor growth.
Tumor Cell Heterogeneity Is No Accident
Genetic Engineering & Biotechnology News — June 21
This Darwinian assertion comes from scientists based at the Moffitt Cancer Center. They deployed a mathematical model based on evolutionary theories to show that certain tumor subpopulations can be predicted and do not develop randomly as previously thought.
Brittni Fest supports leukemia patient
The Daily Advertiser — June 21
Daughter of radio personality C.J. Clements of KTDY 99.9 FM, Brittni began receiving chemotherapy treatments last February at the Moffitt Cancer Center in Tampa, Florida.
Moffitt Hosts Future Doctors
WTSP Channel 10 – June 20
Today, dozens of high school students got a lesson on why they should consider a career in science and technology. They got a chance to meet with the brightest researchers in the world. It is taking place at Moffitt Cancer Center today.
Early results promising for pembrolizumab in combination regimens for NSCLC
PM360 – June 20
“These combinations, while perhaps better than chemotherapy alone, may not be better than just immunotherapy alone, session moderator Dr. Scott Antonia of the Moffitt Cancer Center, Tampa, Fla., commented. “And the truth is that concurrent therapy is clearly more toxic.”
TROD Medical’s prostate focal therapy device, Encag advances in US and UK clinical studies
PharmaBiz.com – June 20
The clinical teams at NYU and UCL presented last month at the 111th American Urological Association’s Annual Meeting (San Diego, CA), on patients treated with Encage. Together with a study running at the Moffitt Cancer Center (Tampa, Florida), over 40 patients have now been treated using Encage. Results not yet published show total tissue destruction in target ablation zones and very significant reduction of side effect (erectile dysfunction and urinary incontinence rates down to 0%).
12 advances in cancer immunotherapy
Healio – June 17
Joseph Markowitz, MD, PhD, medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.